Back to Market Feed

Product Information

DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Apotex Corp., priced at $0.9460 per EA under NDC 60505434906. Its NADAC has been published 88 times since Dec 18, 2024.

FDA first approved this application on Dec 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DABIGATRAN ETEXILATE 110 MG CP

dabigatran etexilate
$0.9460per EA

Strength

110 mg/1

Manufacturer

Apotex Corp.

NDC

60505434906

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208070

FDA Approved

12/15/2023

TE Code

AB

On Market Since

2/13/2024

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 88 times since Dec 18, 2024, and over the history we have for it it has declined 46.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.9460 per EA
All-time high$1.9786 (Apr 16, 2025)
All-time low$0.9196 (May 20, 2026)
52-week high$1.8359
52-week low$0.9196
Median price$1.7431
Average price$1.5267
Largest weekly change-12.4% (Dec 17, 2025)
Weeks tracked88
Tracking sinceDec 18, 2024

Price History

1W

-2.8%

1M

-2.8%

3M

+2.9%

6M

-15.4%

1Y

-48.5%

3Y

N/A

5Y

N/A

All

-46.4%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dabigatran etexilate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

DABIGATRAN ETEXILATE 150 MG CP
Generic
00378026691•Mylan Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
00904725510•Major Pharmaceuticals
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
00904725568•Major Pharmaceuticals
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
31722062232•Camber Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
31722062260•Camber Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
43598064160•Dr. Reddy's Laboratories Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
59651097560•Aurobindo Pharma Limited
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
62332063606•Alembic Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
62332063660•Alembic Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
67877047560•Ascend Laboratories, LLC
$0.8226
per EA

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Apotex Corp., is $0.9460 per EA (NDC 60505434906), effective Aug 19, 2026.

How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 46.4%. It has been tracked across 88 weekly CMS publications since Dec 18, 2024.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?

Since Dec 18, 2024, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.9786 (Apr 16, 2025), with a median of $1.7431 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?

No other NADAC-published product currently shares the active ingredient and strength of DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DABIGATRAN ETEXILATE 110 MG CP?

DABIGATRAN ETEXILATE 110 MG CP (NDC 60505434906) is labeled by Apotex Corp., and CMS classifies it as a generic product.